Research, Policy

Glaukos (GKOS): Pipeline Policy Pathway

John Leppard, Senior Health Care Analyst
04 March 2023

Summary

Following Glaukos’ (GKOS) earnings report, attention now turns to the regulatory processes for core growth products like iDose and iStent Infinite, outlined more broadly in our March 1 deep dive on issues surrounding their approval, coding, coverage, and reimbursement.


Want to learn more? Download the Report.

Solutions

Public Policy Research
Identify opportunity and risks driven by public policy.

Related Insights

Mitigation Expectations for Medicare Advantage Rate Notice

Mitigation Expectations for Medicare Advantage Rate Notice

Size of Medicare Advantage mitigation may be less than earlier expectations...
Read more